Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease

Abstract

Lung disease is a common manifestation of connective tissue disease (CTD) and is associated with significant morbidity and mortality. The evaluation of lung disease, and interstitial lung disease (ILD) in particular, in patients with CTD is complex because of the heterogeneity of the CTDs, the varied types and degrees of severity of ILD encountered, and because ILD can be identified at any point in time in these patients. Cross-disciplinary, thorough evaluations are needed when CTD patients develop ILD or when evaluating ILD patients for the presence of occult CTD. Determining that ILD is associated with an established CTD requires the exclusion of alternative etiologies, and thorough assessments of the clinical features of both the CTD and ILD. The detection of occult CTD in patients with “idiopathic” ILD requires careful attention to the demographic profile, historical clues, subtle physical examination findings, specific autoantibody positivity, radiological and histopathological features, and can be optimized by a multidisciplinary approach that includes rheumatological collaboration. Not all patients with CTD-associated ILD require pharmacological therapy, and management decisions should consider pace and severity of the disease, intra- and extrathoracic features of activity and can be optimized by cross-disciplinary collaboration.

Keywords

connective tissue disease - interstitial lung disease - collagen vascular disease

• References

• 1 Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012; 380 (9842): 689-698
• 2 Fischer A, du Bois RM. A Practical Approach to Connective Tissue Disease-Associated Lung Disease. 2nd ed. New York: Springer; 2012
• 3 Frankel SK, Brown KK. Collagen vascular diseases of the lung. Clin Pulm Med 2006; 13 (1) 25-36
• 4 Olson AL, Brown KK. Connective tissue disease-associated lung disorders. Eur Resp Mon 2009; 46: 225-250
• 5 Steen VD. The lung in systemic sclerosis. J Clin Rheumatol 2005; 11 (1) 40-46
• 6 Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008; 133 (1) 271-280
• 7 Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease?. Eur Respir J 2006; 28 (5) 893-896
• 8 Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185 (11) 1147-1153
• 9 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2) 277-304
• 10 Park JH, Kim DS, Park IN , et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175 (7) 705-711
• 11 Kim EJ, Elicker BM, Maldonado F , et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35 (6) 1322-1328
• 12 Lee HK, Kim DS, Yoo B , et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127 (6) 2019-2027
• 13 Bouros D, Wells AU, Nicholson AG , et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165 (12) 1581-1586
• 14 Kim DS, Yoo B, Lee JS , et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (2) 121-127
• 15 Fischer A, Swigris JJ, du Bois RM , et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009; 103 (11) 1719-1724
• 16 Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2010; 40 (1) 73-88
• 17 Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88 (5) 470-476
• 18 Strange C, Bolster MB, Roth MD , et al; Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177 (1) 91-98
• 19 Goh NS, Veeraraghavan S, Desai SR , et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56 (6) 2005-2012
• 20 Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33 (4) 882-896
• 21 Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103 (8) 1152-1158
• 22 Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA , et al. Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006; 33 (8) 1600-1605
• 23 Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130 (4) 976-981
• 24 Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford) 2011; 50 (3) 489-493
• 25 Corte TJ, Copley SJ, Desai SR , et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39 (3) 661-668
• 26 Raghu G, Collard HR, Egan JJ , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (6) 788-824
• 27 Hwang JH, Misumi S, Sahin H, Brown KK, Newell JD, Lynch DA. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr 2009; 33 (3) 410-415
• 28 Lynch DA. Quantitative CT of fibrotic interstitial lung disease. Chest 2007; 131 (3) 643-644
• 29 Lynch DA, Travis WD, Müller NL , et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236 (1) 10-21
• 30 Fukuoka JLK. Practical Pulmonary Pathology. A Diagnostic Approach. 1st ed. Philadelphia, PA: Churchill-Livingstone; 2005
• 31 Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007; 28 (4) 369-378
• 32 Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136 (1) 23-30
• 33 Flaherty KR, Colby TV, Travis WD , et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167 (10) 1410-1415
• 34 Fischer A, Brown KK, Frankel SK. Treatment of connective tissue disease related interstitial lung disease. Clin Pulm Med 2009; 16 (2) 74-80